PLIANT THERAPEUTICS, INC. (PLRX)
PLIANT THERAPEUTICS, INC. (PLRX)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -20,040 | -23,577 | -26,301 | -99,466 |
| Depreciation expense | 264 | 365 | 436 | 895 |
| Stock-based compensation expense | 4,254 | 4,525 | 6,418 | 15,291 |
| Gain on sale of property plant and equipment | 94 | 0 | 44 | NaN |
| Non-cash operating lease expense | 835 | 828 | 821 | 1,628 |
| Net amortization (accretion) on short-term investments | -417 | -282 | -335 | -3,339 |
| Loss on extinguishment of debt | NaN | -1,828 | NaN | NaN |
| Prepaid expenses and other current assets | -1,724 | 209 | -780 | -1,970 |
| Other non-current assets | -323 | 0 | 0 | -43 |
| Accounts payable | -118 | -3 | -897 | -4,580 |
| Accrued liabilities | -6,474 | -1,514 | -2,031 | -8,622 |
| Operating lease liabilities | -320 | -313 | -598 | 35 |
| Net cash used in operating activities | -19,229 | -17,788 | -21,081 | -89,467 |
| Purchase of short-term investments | 64,900 | 85,085 | 52,563 | 65,756 |
| Maturity of short-term investments | 60,698 | 86,854 | 80,328 | 170,731 |
| Purchase of property and equipment | 0 | 0 | 0 | 374 |
| Proceeds from sale of property, plant and equipment | 102 | -1 | 156 | NaN |
| Net cash (used in) provided by investing activities | -4,100 | 1,768 | 27,921 | 104,601 |
| Payment of debt | NaN | 32,267 | NaN | NaN |
| Proceeds from term loan, net of issuance costs | NaN | 0 | 0 | 0 |
| Proceeds from issuances of common stock under benefit plans | 74 | 0 | 72 | 498 |
| Net cash provided by financing activities | 74 | -32,267 | 72 | 498 |
| Net (decrease) increase in cash and cash equivalents | -23,255 | -48,287 | 6,912 | 15,632 |
| Cash and cash equivalents and restricted cash at beginning of period | 46,927 | 95,214 | 72,670 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 23,672 | 46,927 | 95,214 | NaN |